NasdaqGS:MRNABiotechs
Moderna (MRNA) Settles Vaccine Patent Case With $950 Million Upfront Payment
Moderna (NasdaqGS:MRNA) has settled a long running patent dispute with Arbutus Biopharma and Genevant Sciences related to COVID-19 vaccine technology.
The agreement includes a US$950 million upfront payment from Moderna to Arbutus and Genevant.
The settlement covers lipid nanoparticle technology used in Moderna's COVID-19 vaccine and concludes multi year litigation.
Moderna is a large mRNA therapeutics company best known for its COVID-19 vaccine, which relies on lipid nanoparticle delivery...